IGFBP5: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 29: | Line 29: | ||
{{protein-stub}} | {{protein-stub}} | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 14:24, 17 March 2025
IGFBP5 (Insulin-like Growth Factor Binding Protein 5) is a protein that in humans is encoded by the IGFBP5 gene. It is one of six members of the insulin-like growth factor binding protein (IGFBP) family and plays a key role in cell proliferation, differentiation, and apoptosis.
Function[edit]
IGFBP5 is a secreted protein that binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors.
Clinical significance[edit]
Alterations in the expression of IGFBP5 have been implicated in a variety of diseases, including breast cancer, prostate cancer, pulmonary fibrosis, and rheumatoid arthritis. In breast cancer, high levels of IGFBP5 have been associated with a poor prognosis. In contrast, in prostate cancer, low levels of IGFBP5 have been linked to a poor prognosis. In pulmonary fibrosis and rheumatoid arthritis, IGFBP5 has been shown to promote fibrosis and inflammation, respectively.
Research[edit]
Research into the role of IGFBP5 in disease progression and the development of targeted therapies is ongoing. Several studies have suggested that IGFBP5 could be a potential therapeutic target in cancer and fibrotic diseases.
See also[edit]
- Insulin-like growth factor
- Insulin-like growth factor-binding protein
- Breast cancer
- Prostate cancer
- Pulmonary fibrosis
- Rheumatoid arthritis
References[edit]
<references />

